Partners
Scientific Advisors
Advertent Bio is guided by a scientific advisory board that includes internationally recognized leaders in muscle biology, neuromuscular disease, and translational therapeutics. Their expertise in genetics, disease modeling, and clinical trial design helps shape our development strategy and de‑risk the path from preclinical discovery to patients.
Louis Kunkel, Ph.D.
Dr. Kunkel is a Professor of Genetics and Pediatrics at Harvard Medical School and the Boston Children’s Hospital. He is an internationally recognized geneticist with years of experience and scientific success in deciphering the genetic basis of muscular dystrophies and neuromuscular diseases. Dr. Kunkel is recognized for identifying the dystrophin gene and its mutation status as the underlying cause for Duchenne muscular dystrophy. His current work focuses on developing novel therapies for Duchenne and other muscular dystrophies by targeting known disease modifiers. He has received numerous awards for his research including the prestigious Gairdner Award and the March of Dimes Prize in Developmental Biology. He is a member of the National Academy of Sciences and the American Academy of Arts and Sciences.

Terence A. Partridge, Ph.D.
Dr. Partridge is Professor Emeritus of Genomics and Precision Medicine at the George Washington University School of Medicine, a Senior Investigator at the Children’s National Hospital in Washington DC, and an expert in muscular dystrophy and other muscle disorders. Dr. Partridge is recognized as a founder of the field of muscle regeneration research. He is credited for identifying satellite cells as the source of new muscle fibers in development and regeneration of skeletal muscles after injury. Dr. Partridge’s contributions have led to major technical and conceptual advances that have paved the way for the development of therapeutic approaches to treat muscular dystrophies. He has received numerous awards and honors, and is a member of the British Society for Cell Biology and the American Society for Gene Therapy.

Industry Advisors
We also work with experienced industry and business advisors who have led drug development, partnering, and company‑building efforts across the biotech and pharmaceutical sectors. Their prior contributions have helped refine our corporate strategy, financing plans, and partnering approach as we move toward the clinic.
Philippe Clavel, Ph.D.
Dr. Clavel is the Chief Executive Officer at Curapath, in Valencia, Spain. He received his training at the Engineering School of Physics and Chemistry of Bordeaux (now ENSMAC), and his PhD at the University of Bordeaux. Dr Clavel brings over 25 years of experience in the chemical & pharmaceutical industry, with a focus on the development, manufacturing, and sales of active pharmaceutical ingredients (APIs) and drug delivery solutions. During his tenure at three international companies, first at Rhodia (Solvay), then as General Manager at Sanofi AIS, and later as the Vice President of Pharmaceutical Solutions at Seqens, Dr. Clavel led over 100 development and manufacturing campaigns for pharmaceutical markets. He has experience in driving R&D to commercialization, as well as in business development, and in alliance and CMC outsourcing management.

Holger Kissel, Ph.D.
Dr. Kissel is Senior Vice President Scientific Relations & Liaison at BioNTech in Mainz, Germany. He received his training at the Universities of Mainz and Hamburg, and his PhD at the Sloan Kettering Institute in New York. After postdoctoral training at the Rockefeller University he joined Artemis Pharmaceuticals (now Taconic) in Köln. In 2013 Dr. Kissel joined BioNTech, then an early stage start-up company developing next-generation personalized immunotherapies for cancer and other debilitating diseases. As Director of Business Development Dr. Kissel helped BioNTech advance through early funding rounds to become the largest privately held biotech company in Europe with over 1,000 employees. BioNTech is advancing several drug candidates through clinical trials in global partnerships with Sanofi/Genzyme, Pfizer, Eli Lilly, Genentech/Roche and Bayer.

Jennifer Lachey, Ph.D.
Jennifer Lachey is currently a biotech consultant with a primary focus on preclinical pharmacology and a background in the design and execution of GLP toxicology programs and GMP manufacturing of protein therapies. She has worked mainly on targeting the TGF-β superfamily of proteins to develop therapeutics for the treatment of musculoskeletal, hematologic, and cardiopulmonary diseases. She brings more than 15 years of industry experience in drug discovery and has a proven track record in advancing therapeutics into clinical development. She served as Keros Therapeutics’ Chief Scientific Officer. Prior to that, Dr. Lachey worked at Seres Therapeutics where she contributed to the clinical development of multiple drug programs. Prior to Seres, she led the pharmacology efforts at Ember Therapeutics and at Acceleron Pharma. She received her Ph.D. in Neurobiology from the University of Cincinnati before relocating to Boston to complete her postdoctoral training at Beth Israel Deaconess Medical Center.

Prior Advisors
David S. Bailie, M.D.
Dr. Bailie is the President of the Arizona Institute for Sports, Knees, and Shoulder (AzISKS) in Scottsdale, Arizona. He received his undergraduate training at the University of Michigan and medical training at Indiana University School of Medicine and Northwestern University McGaw Medical Center. Dr. Bailie completed his fellowship in Orthopedic Sports Medicine at the Baylor Sports Medicine Institute in Houston. During his training he helped care for athletes from numerous high schools, as well as professional teams including the Chicago Bulls and the Houston Oilers. Dr. Bailie joined the sports medicine team for the Phoenix Suns in 1996, and The Orthopedic Clinic Association (TOCA) in 1998. In 2015 Dr. Bailie founded AzISKS where he treats sports injuries and degenerative conditions of the knee and shoulder.

Philip Bernstein, Ph.D.
Dr. Bernstein is the Executive Director of Strategic Review and Planning at the Immune Tolerance Network (ITN) at the Benaroya Research Institute. He received his training at the University of Wisconsin, Madison, and the Rockefeller University in New York. After working as an editor at various journals, including Nature Biotechnology, the Journal of Experimental Medicine, and PLoS Biology he became the Head of Scientific Affairs and International Relations at Institute Pasteur-Korea. Dr. Bernstein joined the ITN in 2008. The ITN develops, funds and conducts clinical trials for immune tolerance therapies in the areas of autoimmune disease, allergies, organ transplantation and type I diabetes. Dr. Bernstein has been involved in developing and coordinating numerous clinical trials, including the recent LEAP study to prevent peanut allergies in high-risk infants.

Vicky Rosen, Ph.D.
Dr. Rosen is Professor and Chair of the Department of Developmental Biology at Harvard School of Dental Medicine. Prior to accepting her current position, Dr. Rosen spent the early part of her career as a scientist at Genetics Institute, a biotechnology company in Cambridge, MA. She was a member of the research team that cloned the first Bone Morphogenetic Protein (BMP) gene in 1988. BMPs belong to a subgroup of TGF-β growth factors that play key roles in the development, maintenance, and repair of musculoskeletal tissues including bone, cartilage, tendon, and muscle. Dr. Rosen then became a professor in the Faculty of Medicine in 2001 and Chair of the Department of Developmental Biology at HSDM in 2005, where she continues to study the roles of BMPs and other TGF-β family growth factors on muscle and bone development.

Sponsors
Advertent Bio has received support from a syndicate of institutional, venture, and strategic investors as well as state and regional innovation organizations, including the following. This diversified support underscores external confidence in our science, team, and development plan.











